UAE
Bahrain
Jordan
Kuwait
Oman
Qatar
Saudi ArabiaHealth News
Medicare Changes: What You Need To Know Now
Date: Jun-28-2012Today, many hospitals are filled to capacity, and as a consequence, physicians are continually pressured to discharge their patients as quickly as possible. Because of inefficiencies in how they communicate with case managers, nurses, and patients, patients are frequently discharged with many loose ends. Recognizing these realities, the new Medicare reimbursement rules will force hospitals and doctors to give a 30-day guarantee for any hospital treatment. If the patient is readmitted within 30 days for the same ailment, Medicare won't pay the hospital...
Another Parkinson's Disease Gene Identified
Date: Jun-28-2012An international team led by human genetic researchers at the University of British Columbia and Vancouver Coastal Health has identified the latest gene associated with typical late-onset Lewy body Parkinson's disease (PD), with the help of a Canadian Mennonite family of Dutch-German-Russian ancestry. Twelve of the 57 members of the Saskatchewan family who participated in the study had previously been diagnosed with PD. UBC Medical Genetics Prof...
Gout And Hyperuricemia On The Rise In The U.S.
Date: Jun-28-2012Boston University School of Medicine (BUSM) researchers have found that the incidence of gout and hyperuricemia (high uric acid levels) in the U.S. has risen significantly over the last 20 years and is associated with major medical disorders like hypertension and chronic kidney disease. The study, which is published in the American Journal of Medicine, was led by Hyon Choi, MD, DrPH, professor of medicine in the section of rheumatology and the clinical epidemiology unit at BUSM and rheumatologist at Boston Medical Center (BMC)...
Neural Activity Modulated By Tiny Magnetic Coils, May Be Safer For Deep-Brain Implants
Date: Jun-28-2012Magnetic fields generated by microscopic devices implanted into the brain may be able to modulate brain-cell activity and reduce symptoms of several neurological disorders. Micromagnetic stimulation appears to generate the kind of neural activity currently elicited with electrical impulses for deep brain stimulation (DBS) - a therapy that can reduce symptoms of Parkinson's disease, other movement disorders, multiple sclerosis and chronic pain - and should avoid several common problems associated with DBS, report Massachusetts General Hospital investigators...
Aeris Therapeutics' AeriSeal® System Clinical Data Demonstrate Improved Lung Function For Up To One Year In Advanced Emphysema Patients
Date: Jun-28-2012Aeris Therapeutics, LLC have announced the publication in CHEST of data from its latest AeriSeal® System clinical trial. In the study, patients with advanced emphysema were treated with the AeriSeal System under conscious sedation. Patients experienced improved lung function for up to one year following the AeriSeal System treatment, with results similar to those reported following lung volume reduction surgery (LVRS)...
Detecting Streptococcal Infection In Newborns Using Improved Diagnostic Test
Date: Jun-28-2012A more accurate, faster diagnostic test for Group B Streptococcal infection in babies has been reported in the Journal of Medical Microbiology. The new test could allow better treatment and management of the disease and reduce the risk of mortality among newborns. Group B streptococcus (GBS) infections, caused by the bacterium Streptococcus agalactiae, are the most common cause of meningitis, septicaemia and pneumonia in newborns. In 2010 there were 506 cases of GBS infections in infants across England, Wales and Northern Ireland...
Glucose Deprivation Activates Feedback Loop That Kills Cancer Cells
Date: Jun-28-2012Compared to normal cells, cancer cells have a prodigious appetite for glucose, the result of a shift in cell metabolism known as aerobic glycolysis or the "Warburg effect." Researchers focusing on this effect as a possible target for cancer therapies have examined how biochemical signals present in cancer cells regulate the altered metabolic state. Now, in a unique study, a UCLA research team led by Thomas Graeber, a professor of molecular and medical pharmacology, has investigated the reverse aspect: how the metabolism of glucose affects the biochemical signals present in cancer cells...
The Best Way To Treat Problem Alcohol Use; Scientists Weigh The Evidence
Date: Jun-28-2012Scientists from the Centre for Addiction and Mental Health (CAMH) have released comprehensive reviews of the most effective treatments for alcohol dependence, one of the most prevalent addictions in Canada. Published in the latest edition of the Canadian Journal of Psychiatry, the reviews explore the most effective treatments and interventions for problem alcohol use and concurrent disorders. Almost 40 per cent of people with an alcohol use problem also have a concurrent mental illness, particularly schizophrenia, mood or anxiety disorders...
Elekta's Agility Radiation Therapy Beam-Shaping Innovation For Cancer Treatments Receives U.S. 510(k) Clearance
Date: Jun-28-2012Utilizing new and faster technology, Agility multi-leaf collimator (MLC) expected to further improve therapy for oncology patients, accelerate treatment times Using a combination of 160 high-resolution tungsten leaves and dramatically faster leaf movement, Elekta's revolutionary new Agility™* MLC promises a new level of precision and delivery speed in radiation therapy treatments for cancer patients. Elekta recently received 510(k) clearance (K121328) from the U.S. Food and Drug Administration (FDA) for Agility, enabling U.S...
COPD Drug Seebri(R) Breezhaler(R) Receives Positive CHMP Opinion
Date: Jun-28-2012COPD patients in Phase III GLOW trials experienced improved lung reduced shortness of breath, reduced exacerbations, and improved quality of life[1,2,3,4] Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) confirms the information Released last week by Novartis that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Seebri(R) Breezhaler(R) (glycopyrronium/NVA237) 44 mcg delivered dose (50 mcg glycopyrronium per capsule), as a once-daily inhaled maintenance bronchodilator treatment to relieve ...
Stay Connected
